Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT03522584 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Terminated by the sponsor due to lack of efficacy in study treatment.

Conditions

Metastatic Head and Neck Squamous Cell Carcinoma
Recurrent Head and Neck Squamous Cell Carcinoma

Interventions

BIOLOGICAL: Durvalumab
OTHER: Laboratory Biomarker Analysis
RADIATION: Stereotactic Body Radiation Therapy
BIOLOGICAL: Tremelimumab
PROCEDURE: Hypofractionated Image-Guided Radiation Therapy

Sponsor

University of Washington

Collaborators

[object Object]
[object Object]